Skip to main content
  • NOVEL SYNTHETIC APPROACHES FOR THE TREATMENT OF MALIGNANT MELANOMA UNDER CLINICAL TRIAL

    ABOUT AUTHORS:
    Tara Shankar Basuri1*, Ishvar Parmar1, Vishal Modi2, Virag Shah3, Niyatee Thakur4
    SSR College of pharmacy, Silvassa,
    U.T of Dadra & Nagar Haveli-396230
    *tbasuri@gmail.com

    ABSTRACT
    Malignant melanoma is the most lethal form of skin cancer and anincreasingly common disease worldwide. It remains one of the most treatment-refractorymalignancies. The current treatment options for patients with metastatic melanoma arelimited and in most cases non-curative. This review focuses on novel synthetic and herbal drugs for malignant melanoma treatment, by a single or combinational agent approach. These molecules are widely used by the oncologists for the treatment of this type of cancer. So this review can help to the public to aware the malignant melanoma and its treatment and novel target for its treatment.

  • PHARMACOVIGILANCE SYSTEM IN WORLD

    ABOUT AUTHOR:
    Vishwa Deepak kumar
    Departement of Pharmacy,
    IEC group of institution,
    Greater Noida (U.P), Pin- 201301
    vdkumar.iec@gmail.com

    ABSTRACT:
    Pharmacovigilance is an important and integral part of clinical research. Pharmacovigilance is “defined as the pharmacological science relating to the detection, assessment, understanding and prevention of adverse effects, particularly long term and short term adverse effects of medicines. This addresses what exactly is Pharmacovigilance?  What do we know of its benefits and risks, challenges and the future hold for pharmacovigilance in Indian medicine. Here the main focus on the aims and role of Pharmacovigilance in medicines regulation and their Partners. This article describes and discusses the National programme of pharmacovigilance and centre in India. There role in collecting the reports ADRs of medicines. Further effectiveness and risk assessments of therapies are been discussed. The important role played by health care professional, pharmaceutical industries, media, and programmes carried by WHO. Finally the conclusion describes the major challenges and achievements for the future pharmacovigilance programmeand toxicity is not socritical if botanicals are used in traditional forms (Harborne., 1998).

  • TO ASSESS THE HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH OSTEOARTHRITIS

    About Author:
    Nishith Sheth
    M.Sc in Clinical Research
    Cranfield university
    sheth10687@gmail.com

    Abstract
    Osteoarthritis is one type of degenerative joint disease and also known as chronic musculoskeletal disease and it occurs mainly in elderly patients with the severe cause of disability. There are approximately 30 million persons affected with severe osteoarthritis and about 26 million persons are affected with severe osteoarthritis in United States only. The approximate annual cost to the public society in medical care is expected to reach 100 billion dollars by the end of 2020. From this much of cost, most of the cost is spent only in finding out the new diagnosis and treatment for this severe disease and also for the prevention of side effects. Today till 2010, 50% of the persons with the age over 75 suffer from the knee osteoarthritis. 80% of the aged persons with knee osteoarthritis feel difficulty in daily routine activities, while 20 % of the aged persons with mild osteoarthritis feel no difficulty in their daily routine activities.
    In this disorder, the joint loses the slippery cartilage those results from ‘wear and tear’ on a joint. Thus the joint becomes large, thick and painful. Thus the bone near the cartilage tries to change and produce overgrowth of the bone.  That’s why the tissue near the bone becomes inflamed and ligaments lose and joint muscle becomes weak. So the people with osteoarthritis feel pain when they are doing their normal routine activities.

  • PHARMACOVIGILANCE: THE PRESENT STATUS AND FUTURE PROSPECTS IN INDIA

    About Authors:
    Roohi Kesharwani1*, Devendra Singh2, Vishal Jacob1
    1-Institute Of Foreign Trade And Management Lodhipur Rajput,
    Delhi Road, Moradabad, India
    2-Raj Kumar Goel Institute Of Technology, Delhi-Meerut Road, Ghaziabad, India
    *roohi4mail@gmail.com, devendrasingh.pisces@gmail.com

    ABSTRACT:
    Pharmacovigilance is now accepted to be a continuous process of evaluation accompanied by steps to improve safe use of medicines which involves pharmaceutical companies, regulatory authorities, health professionals and patients. The methodologies have broadened to encompass many different types of study, with spontaneous reporting remaining the cornerstone. The concern for ADRs in highly vulnerable populations is of even greater concern.Pharmacovigilance is especially important since most of the adverse effects are reversible by modifying the dosage or omitting the offending medicine. All medicines (pharmaceuticals and vaccines) haveside effects.In a vast country like India with a population of over 1.2 Billion with vast ethnic variability, different disease prevalence patterns, practice of different systems of medicines, different socioeconomic status, it is important to have a standardized and robust pharmacovigilance and drug safety monitoring programme for the nation.  Collecting this information in a systematic manner and analyzing the data to reach a meaningful conclusion on the continued use of these medicines is the rationale to institute this program for India. In this review article various hospitals survey are done and the  survey questionnaire was analyzed question wise and their percentage value was calculated. Our study strongly suggests that there is greater need to create awareness and to promote the reporting of ADR among healthcare professionals of the country. Only such approach can greatly influence in bringing reporting culture among healthcare professionals and may improve the reporting rates of ADR in our country. Pharmacists, as doctors opined that their involvement may increase the reporting rate, have a greater role to play in the area of pharmacovigilance.

  • REVIEW ON CLINICAL TRIALS

    About Authors:
    Kambham Venkateswarlu

    Final Year Graduate Student
    Sri Lakshmi Narasimha College of Pharmacy,
    Palluru, Chittoor-517132, Andhra Pradesh, India.
    k.v.reddy9441701016@gmail.com

    ABSTRACT:
    Clinical trials are the set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for place only interventions. These trials can take place only after satisfactory information has been gathered on the quality of the country where the trial is taking place.

    Depending on the type of product and the stage of its development, investigators enrol healthy volunteers and patients into small pilot studies, followed by larger scale studies in patients that often compare the new product with the currently prescribed treatment. As positive safety and efficacy data are gathered, the number of patients is typically increased. Clinical trials can vary in size from a single centre in one country to multicenter trials in multiple countries.

  • HIV / AIDS EVOLUTION AND CONSIDERATIONS

    About Authors:
    Nishant kumar singh
    Research Fellow,
    ICRI (Ahm) and Cranfield University

    * nishantsingh.shree@gmail.com

    ABSTRACT:
    Over 3 decades HIV/AIDS have been a major globally accepted challenge, from endemic to a catastrophic pandemic & explodes globally. Estimates says 33.3 million HIV +ve and 2.6 million newly HIV infected people are in 2009. Since the beginning of epidemic, nearly 30 million people have died from AIDS related cause[1].  From chimpanzees to human[2] and then human to human (migration[3], MSM, HS, IDU, MTC etc) and ultimately it transformed into pandemic. After 30 years we have advanced our treatment & Medicare knowledge of HIV and AIDS. Our scientist has developed several successful targets and drugs based on them, a highly effective therapy HAART currently in use (managing viral load & cell count for better patient survival rate) showing good results. Still HIV/AIDS is incurable, WHY? It shows the need of critical thinking from the very 1st initial step i.e. TARGET. HIV itself is the target; biotech and Pharmaceutical Company must consider nanotechnology & homologous approach for CCR5. Though it seems that we have control over it but if this goes out same way, than one day just due to the HIV typical characteristic of mutation and recombination the worst Catastrophic sub Saharan-Africa epidemic will become Pandemic.[i]

  • THROMBOPHILIA AND VENOUS THROMBOEMBOLISM IN PREGNANCY: DETECTION AND MANAGEMENT PARADIGM

    About Authors:
    Ritesh Shah*, Gaurav Chandawat, Rahul Jadav, Bhoomi Arora
    Institute Of Clinical Research (India),
    Ahmedabad, Gujarat-380013, India
    *ritesh_shah99@yahoo.com

    ABSTRACT
    Venous thromboembolism (VTE) complicates approximately 1 to 2 of 1,000 pregnancies, with pulmonary embolism (PE) being a leading cause of maternal mortality and deep vein thrombosis (DVT) an important cause of maternal morbidity. The main reason for the increased risk of thromboembolism in pregnancy is hypercoagulability, which has likely evolved to protect women from the bleeding challenges of miscarriage and childbirth. Women are at a 4- to 5-fold increased risk of thromboembolism during pregnancy and the postpartum period compared with when they are not pregnant. Eighty percent of the thromboembolic events in pregnancy are venous, with an incidence of 0.61 to 1.72 per 1000 pregnancies.Includes a history of thrombosis, inherited and acquired thrombophilia, maternal age greater than 35, certain medical conditions, and various complications of pregnancy and childbirth.

    Despite the increased risk of VTE during pregnancy and the postpartum period, most women do not require anticoagulation. The intensity of the anticoagulation will depend on the indication and the monitoring will depend on the intensity. At the time of delivery, anticoagulation should be manipulated to reduce the risk of bleeding complications while minimizing the risk of thrombosis. There are no large trials of anticoagulants in pregnancy, and recommendations are based on case series, extrapolations from nonpregnant patients and the opinion of experts. Nonetheless, anticoagulants are believed to improve the outcome of pregnancy for women who have, or have had, VTE.

  • A REVIEW ON DEVELOPMENT OF ANTIBIOTIC RESISTANCE AND SURVEY OF PHYSICIANS PRESCRIPTION HABBITS IN MANDSAUR

    About Authors:
    Vishal Sharma1*, Alankar Shrivastava2
    1Department of Pharmaceutics,
    2Senior Lecturer Department of Pharmaceutical Analysis
    B.R.NAHATA COLLEGE OF PHARMACY
    (A SIRO Recognized by DSIR, Ministry of science & Technology, GOI)
    MANDSAUR (M.P.) 458001
    *vishus2010@gmail.com

    Abstract
    Antibiotics are chemical substances, either produced naturally by microorganisms or manufactured synthetically, that are lethal to other microorganisms. Antibiotic resistance (AR) describes the ability of a microorganism to be unaffected by (or resistant to) the effects of a particular antibiotic. A problem arises when a animal or person becomes infected with a disease-causing bacterium that harbors antibiotic resistance to the drug that would be the most suitable treatment for that infection.

    India is a vast country of immense diversity.and for that the effectiveness of the antimicrobial was not same to all ,and the administration of them will either really cure or may act in opposite manner and will leads to the development os the antimicrobial resistance which is only due to the unaware use of the antibiotics.we had conducted the survey on some prescriptions of registered medicinal practitioner and find that there was an irrational use of antibiotic in our on community and this might be very serious as our survey is on the smallest level and what it may cause globally.So the use of antibiotic should be controlled.

  • BULLOUS PEMPHIGOID

    About Authors:
    Patel Punita s*, Patel Brilina M, Arora Bhoomi
    Institute of clinical research India
    ahmedabad, Gujarat
    *
    punitapatel_icri@ymail.com

    Abstract:
    Bullous Pemphigoid (BP) is an autoimmune subepidermal blistering disease appearing predominantly in the elderly. Bullous Pemphigoidcharacterized by an autoimmune response to 2 hemidesmosomal proteins within the dermal–epidermal junction, These proteins, called BP antigen 1 (BPAG1 or AgBP230), and BPAG2 (or AgBP180 or collagen XVII) have respective molecular masses of 230 and 180. While BP180 is a transmembrane glycoprotein with an extracellular domain BP230 localizes intracellularly and associates with the hemidesmosomal plaque. The disease is characterized clinically by tight bullae, with clear content, often large, developing primarily on the edge of erythematous plaques. Intense itching is common. The disease is primarily treated with systemic corticosteroids. Now,The increased knowledge of the development of noveltherapeutic strategies for Bullous Pemphigoids.

  • A REVIEW ARTICLE ON: GENERAL CONSIDERATIONS FOR CLINICAL TRIALS (ICH EFFICACY TOPIC E8) AND MARKETING AUTHORIZATION

    About Authors:
    Vinay K. Gupta*, G. Rajan and  Preeti Kothiyal
    Shree Guru Ram  Rai Institute of Technology  & Science,
    Patel Nagar, Dehradun
    *vngupta74@gmail.com

    Abstract
    The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is unique in bringing together the regulatory authorities and pharmaceutical industry of Europe, Japan and the US to discuss scientific and technical aspects of drug registration. Since its inception in 1990, ICH has evolved, through its ICH Global Cooperation Group, to respond to the increasingly global face of drug development, so that the benefits of international harmonization for better global health can be realized worldwide. ICH's mission is to achieve greater harmonization to ensure that safe, effective and high quality medicines. This contains four main topic that are Quality, Safety, Efficacy and Multidisplinary. Here we are mainly explain general aspects of clinical trial that are related to ICH E8 and procedure for marketing authorization of new drug substance in India

Subscribe to CR Articles